(Q34291279)

1 August 2017

1 reference

title

Stopping rules for phase II studies (English)

1 reference

1 August 2017

1

N Stallard

1 reference

1 August 2017

J Whitehead

2

1 reference

1 August 2017

S Todd

series ordinal

3

1 reference

1 August 2017

A Whitehead

series ordinal

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

British Journal of Clinical Pharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

51

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

523-529

1 reference

Interim analyses and sequential designs in phase III studies

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

Decision theoretic designs for phase II clinical trials with multiple outcomes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

Approximately optimal designs for phase II clinical studies.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

Sample size determination for phase II clinical trials based on Bayesian decision theory

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

Bivariate sequential designs for phase II trials.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

A two-stage design for choosing among several experimental treatments and a control in clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

Optimal two-stage designs for phase II clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

Practical Bayesian guidelines for phase IIB clinical trials.

6 July 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01381.X

A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01381.X

Bayesian interim analysis of phase II cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01381.X

Designing phase II studies in the context of a programme of clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01381.X

Sequential designs for phase III clinical trials incorporating treatment selection

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014484

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

28 October 2018

1 reference

12 December 2020

Statistical considerations for pilot studies

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

Sample sizes for phase II and phase III clinical trials: an integrated approach

1 reference

12 December 2020

An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives

1 reference

12 December 2020

10.1046/J.0306-5251.2001.01381.X

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference